Death of frontline allo-SCT in myeloma

Abstract

In this issue of Blood, Lokhorst et al report the results of a donor versus no-donor comparison trial, which unambiguously establishes that reduced intensity conditioning allogeneic stem cell transplantation (RIC allo-SCT) should not be offered as part of frontline therapy in multiple myeloma (MM) 1.